News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Kisqali (ribociclib) given alongside endocrine therapy as adjuvant therapy for patients with stage 2 or 3 hormone receptor-positive, HER2-negative breast cancer reduced patients’ risk for ...

Ibrance failed the PALLAS trial as adjuvant treatment for early breast ... playing catch-up in the category with Novartis’ Kisqali (ribociclib), which got a green light four years ago following ...

Lipopolysaccharide functions as a vaccine adjuvant but is considered too toxic for clinical use. The major structural element responsible for its toxicity and adjuvant effect is lipid A.

Adjuvants alone are not licensed; a specific adjuvant/antigen formulation is licensed. This implies that the development of an adjuvant is strictly related to the antigen present in the specific ...

Get detailed information on Ribociclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with ...

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions.